A multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of AGB101 (low-dose levetiracetam, 220 mg, extended release tablet) on slowing progression of mild cognitive impairment due to Alzheimer's disease

    Not Recruiting
Updated on 25 September 2022
cognitive impairment
vitamin e
mini-mental state examination
cognitive decline
mild cognitive impairment
cholinesterase inhibitors
ginkgo biloba


A study for patients with mild cognitive impairment due to Alzheimer's disease with short memory loss.


Free consultations and study related tests and compensation for time and travel.

Condition Alzheimer's Disease, Alzheimer's Disease
Clinical Study IdentifierTX228645
Last Modified on25 September 2022

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note